This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Jazz Pharmaceuticals plc
5/5/2026
Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals' 2026 first quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised, that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, John Ballou, Head of Investor Relations. Please go ahead.
Thank you, and good afternoon, everyone.
Today, Jazz Pharmaceuticals reported its first quarter 2026 financial results. The slide presentation accompanying this webcast is available on the investor section of our website, along with a press release and quarterly report on Form 10Q for the first quarter ended March 31st, 2026. On the call today are Renee Galla, President and Chief Executive Officer, Sam Pearce, Chief Commercial Officer, Robbie Annone, Global Head of R&D and Chief Medical Officer, and Phil Johnson, Chief Financial Officer. On slide two, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance, and results differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption risk factors in our annual report on Form 10-K for the fiscal year ended December 31, 2025. We undertake no duty or obligation to update our forward-looking statements. As noted on slide three, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the investor section of our website. I'll now turn the call over to Renee.
You're reading a preview of the JAZZ Q1 2026 earnings call.
Free account.